FLT3 and acute myeloid leukemia: Here, the FLT3 expression was negatively correlated with riskScore and prognosis of patients with AML, patients with low FLT3 combined with low riskScore had significantly better overall survival than others, and those with low riskScore had more sensitivity to its inhibitors, such as drugs like sorafenib and the recently approved midostaurin for relapsed or refractory FLT3-mutant AML (Antar et al., 2017; Brinton et al., 2020; Döhner et al., 2020).